Isis Biopolymer, a Providence, RI-based developer of drug-delivery devices, has raised $3 million in equity financing, according to an SEC filing. The document does not list the investors in the round, and company CEO Emma Durand was not immediately available for comment this afternoon. The company says on its website that it was founded in 2006 and has developed a patch—embedded computer chips, thin-film batteries, and other technology—to deliver drugs through the skin.
Author: Ryan McBride
Ryan is an award-winning business journalist who contributes to our life sciences and technology coverage. He was previously a staff writer for Mass High Tech, a Boston business and technology newspaper, where he and his colleagues won a national business journalism award from the Society of American Business Editors and Writers in 2008. In recent years, he has made regular TV appearances on New England Cable News.
Prior to MHT, Ryan covered the life sciences, technology, and energy sectors for Providence Business News. He graduated with honors from the University of Rhode Island in 2001 with a bachelor’s degree in communications. When he’s not chasing down news, Ryan enjoys mountain biking and skiing in his home state of Vermont.
View all posts by Ryan McBride
